China · Delayed Price · Currency is CNY GemPharmatech Statistics
Total Valuation
GemPharmatech has a market cap or net worth of CNY 7.67 billion. The enterprise value is 6.80 billion.
| Market Cap | 7.67B |
| Enterprise Value | 6.80B |
Important Dates
The next estimated earnings date is Thursday, April 23, 2026.
| Earnings Date | Apr 23, 2026 |
| Ex-Dividend Date | Nov 20, 2025 |
Share Statistics
GemPharmatech has 410.00 million shares outstanding. The number of shares has decreased by -1.19% in one year.
| Current Share Class | 410.00M |
| Shares Outstanding | 410.00M |
| Shares Change (YoY) | -1.19% |
| Shares Change (QoQ) | -4.67% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 13.46% |
| Float | 161.79M |
Valuation Ratios
The trailing PE ratio is 62.35 and the forward PE ratio is 60.98.
| PE Ratio | 62.35 |
| Forward PE | 60.98 |
| PS Ratio | 10.19 |
| PB Ratio | 3.48 |
| P/TBV Ratio | 3.56 |
| P/FCF Ratio | 102.43 |
| P/OCF Ratio | 39.65 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 32.47, with an EV/FCF ratio of 90.80.
| EV / Earnings | 55.93 |
| EV / Sales | 9.03 |
| EV / EBITDA | 32.47 |
| EV / EBIT | 64.46 |
| EV / FCF | 90.80 |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 0.15.
| Current Ratio | 3.30 |
| Quick Ratio | 3.00 |
| Debt / Equity | 0.15 |
| Debt / EBITDA | 1.56 |
| Debt / FCF | 4.37 |
| Interest Coverage | 19.02 |
Financial Efficiency
Return on equity (ROE) is 5.62% and return on invested capital (ROIC) is 7.23%.
| Return on Equity (ROE) | 5.62% |
| Return on Assets (ROA) | 2.46% |
| Return on Invested Capital (ROIC) | 7.23% |
| Return on Capital Employed (ROCE) | 4.61% |
| Revenue Per Employee | 476,993 |
| Profits Per Employee | 77,000 |
| Employee Count | 1,578 |
| Asset Turnover | 0.28 |
| Inventory Turnover | 4.44 |
Taxes
In the past 12 months, GemPharmatech has paid 18.67 million in taxes.
| Income Tax | 18.67M |
| Effective Tax Rate | 13.32% |
Stock Price Statistics
The stock price has increased by +34.33% in the last 52 weeks. The beta is 0.57, so GemPharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.57 |
| 52-Week Price Change | +34.33% |
| 50-Day Moving Average | 16.70 |
| 200-Day Moving Average | 15.50 |
| Relative Strength Index (RSI) | 64.03 |
| Average Volume (20 Days) | 4,197,092 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemPharmatech had revenue of CNY 752.70 million and earned 121.51 million in profits. Earnings per share was 0.30.
| Revenue | 752.70M |
| Gross Profit | 469.55M |
| Operating Income | 105.43M |
| Pretax Income | 140.18M |
| Net Income | 121.51M |
| EBITDA | 198.32M |
| EBIT | 105.43M |
| Earnings Per Share (EPS) | 0.30 |
Balance Sheet
The company has 1.20 billion in cash and 327.40 million in debt, with a net cash position of 871.09 million or 2.12 per share.
| Cash & Cash Equivalents | 1.20B |
| Total Debt | 327.40M |
| Net Cash | 871.09M |
| Net Cash Per Share | 2.12 |
| Equity (Book Value) | 2.20B |
| Book Value Per Share | 5.37 |
| Working Capital | 1.25B |
Cash Flow
In the last 12 months, operating cash flow was 193.39 million and capital expenditures -118.54 million, giving a free cash flow of 74.85 million.
| Operating Cash Flow | 193.39M |
| Capital Expenditures | -118.54M |
| Free Cash Flow | 74.85M |
| FCF Per Share | 0.18 |
Margins
Gross margin is 62.38%, with operating and profit margins of 14.01% and 16.14%.
| Gross Margin | 62.38% |
| Operating Margin | 14.01% |
| Pretax Margin | 18.62% |
| Profit Margin | 16.14% |
| EBITDA Margin | 26.35% |
| EBIT Margin | 14.01% |
| FCF Margin | 9.94% |
Dividends & Yields
This stock pays an annual dividend of 0.14, which amounts to a dividend yield of 0.76%.
| Dividend Per Share | 0.14 |
| Dividend Yield | 0.76% |
| Dividend Growth (YoY) | -26.32% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 50.06% |
| Buyback Yield | 1.19% |
| Shareholder Yield | 1.95% |
| Earnings Yield | 1.58% |
| FCF Yield | 0.98% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
GemPharmatech has an Altman Z-Score of 6.79 and a Piotroski F-Score of 5.
| Altman Z-Score | 6.79 |
| Piotroski F-Score | 5 |